Clinical Trial Update: Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating MT1013 Injection for secondary hyperparathyroidism in chronic kidney disease patients on maintenance hemodialysis. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• MT1013 Injection (MT1013)

Snippet

Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Status: RECRUITING